Acquired thrombocytopenia

Neonatal Hematology: Pathogenesis, Diagnosis, and Management of Hematologic Problems, Second Edition

Volumn , Issue , 2010, Pages 157-171

  Sola Visner, Martha C ^a   Saxonhouse, Matthew A ^b  

^a HARVARD UNIVERSITY   (United States)

^b Pediatrix Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84924180825     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511978135.013     Document Type: Chapter

References (96)

1. Aballi AJ, Puapondh Y, Desposito F. Platelet counts in thriving premature infants. Pediatrics 1968;42:685-9.
2. Ablin AR, Kushner JH, Murphy A, et al. Platelet enumeration in the neonatal period. Pediatrics 1961;28:822-4.
3. Sell EJ, Corrigan JJ, Jr. Platelet counts, fibrinogen concentrations, and factor V and factor VIII levels in healthy infants according to gestational age. J Pediatr 1973;82:1028-32.
4. Wiedmeier SE, Elenry E, Sola-Visner MC, et al. Platelet reference ranges for neonates, defined using data from over 47,000 patients in a multihospital healthcare system. JPerinatol 2009;29:130-6.
5. McPherson RJ, Juul S. Patterns of thrombocytosis and thrombocytopenia in hospitalized neonates. J Perinatol 2005;25:166-72.
6. Dreyfus M, Kaplan C, Verdy E, et al. Frequency of immune thrombocytopenia in newborns: a prospective study. Immune hrombocytopenia Working Group. Blood 1997;89:4402-6.
7. Uhrynowska M, Maslanka K, Zupanska B. Neonatal thrombocytopenia: incidence, serological and clinical observations. Am JPerinatol 1997;14:415-18.
8. Castle V, Andrew M, Kelton J, et al. Frequency and mechanism of neonatal thrombocytopenia. J Pediatr 1986;108:749-55.
9. Mehta P, Vasa R, Neumann L, et al. Thrombocytopenia in the high-risk infant. J Pediatr 1980;97:791-4.
10. Oren H, Irken G, Oren B, et al. Assessment of clinical impact and predisposing factors for neonatal thrombocytopenia. Indian J Pediatr 1994;61:551-8.
11. Christensen RD, Henry E, Wiedmeier SE, et al. Thrombo cytopenia among extremely low birth weight neonates: data from a multihospital healthcare system. J Perinatol 2006;26:348-53.
12. Sola MC, Slayton WB, Rimsza LM, et al. A neonate with severe thrombocytopenia and radio-ulnar synostosis. J Perinatol 2004;24:528-30.
13. Tighe P, Rimsza LM, Christensen RD, et al. Severe thrombocytopenia in a neonate with congenital HIV infection. J Pediatr 2005;146:408-13.
14. Saxonhouse MA, Manco-Johnson MJ. He evaluation and management of neonatal coagulation disorders. Semin Perinatol 2009;33:52-65.
15. Murray NA, Watts TL, Roberts IA. Endogenous thrombopoietin levels and effect of recombinant human thrombopoietin on megakaryocyte precursors in term and preterm babies. Pediatr Res 1998;43:148-51.
16. Sola MC, Calhoun DA, Hutson AD, et al. Plasma thrombopoietin concentrations in thrombocytopenic and non-thrombocytopenic patients in a neonatal intensive care unit. Br J Haematol 1999;104:90-2.
17. Walka MM, Sonntag J, Dudenhausen JW, et al. Thrombopoietin concentration in umbilical cord blood of healthy term newborns is higher than in adult controls. Biol Neonate 1999;75:54-8.
18. Nishihira H, Toyoda Y, Miyazaki H, et al. Growth of macroscopic human megakaryocyte colonies from cord blood in culture with recombinant human thrombopoietin (c-mpl ligand) and the effects of gestational age on frequency of colonies. Br J Haematol 1996;92: 23-8.
19. Olson TA, Levine RF, Mazur EM, et al. Megakaryocytes and megakaryocyte progenitors in human cord blood. Am J Pediatr Hematol Oncol 1992;14:241-7.
20. de Alarcon PA, Graeve JL. Analysis of megakaryocyte ploidy in fetal bone marrow biopsies using a new adaptation of the Feulgen technique to measure DNA content and estimate megakaryocyte ploidy from biopsy specimens. Pediatr Res 1996;39:166-70.
21. Hegyi E, Nakazawa M, Debili N, et al. Developmental changes in human megakaryocyte ploidy. Exp Hematol 1991;19: 87-94.
22. Mattia G, Vulcano F, Milazzo L, et al. Different ploidy levels of megakaryocytes generated from peripheral or cord blood CD34+ cells are correlated with different levels of platelet release. Blood 2002;99:888-97.
23. Harker LA. Kinetics of thrombopoiesis. J Clin Invest 1968;47: 458-65.
24. Harker LA, Finch CA. T rombokinetics in man. J Clin Invest 1969;48:963-74.
25. Sola-Visner MC, Christensen RD, Hutson AD, et al. Megakaryocyte size and concentration in the bone marrow of thrombocytopenic and nonthrombocytopenic neonates. Pediatr Res 2007;61:479-84.
26. Hu ZSW, Rimsza L, Bailey M, Sallmon H, Sola-Visner M. Differences between newborn and adult mice in their response to immune thrombocytopenia. Neonatology In Press.
27. Kaushansky K. Lineage-specific hematopoietic growth factors. NEngl J Med 2006;354:2034-45.
28. Dame C. Trombopoietin in thrombocytopenias of childhood. Semin hromb Hemost 2001;27:215-28.
29. Murray NA, Roberts IA. Circulating megakaryocytes and their progenitors (BFU-MK and CFU-MK) in term and pre-term neonates. Br J Haematol 1995;89:41-6.
30. Murray NA, Roberts IA. Circulating megakaryocytes and their progenitors in early thrombocytopenia in preterm neonates. Pediatr Res 1996;40:112-9.
31. Ault KA, Knowles C. In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp Hematol 1995;23:996-1001.
32. Ault KA, Rinder HM, Mitchell J, et al. The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. Am J Clin Pathol 1992;98:637-46.
33. Joseph MA, Adams D, Maragos J, et al. Flow cytometry of neonatal platelet RNA. J Pediatr Hematol Oncol 1996;18:277-81.
34. Peterec SM, Brennan SA, Rinder HM, et al. Reticulated platelet values in normal and thrombocytopenic neonates. J Pediatr 1996;129:269-74.
35. Saxonhouse MA, Sola MC, Pastos KM, et al. Reticulated platelet percentages in term and preterm neonates. J Pediatr Hematol Oncol 2004;26:797-802.
36. Jilma-Stohlawetz P, Homoncik M, Jilma B, et al. Fligh levels of reticulated platelets and thrombopoietin characterize fetal thrombopoiesis. Br J Haematol 2001;112: 466-8.
37. Briggs C, Kunka S, Hart D, et al. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol 2004;126:93-9.
38. Cremer M, Paetzold J, Schmalisch G, et al. Immature platelet fraction as novel laboratory parameter predicting the course of neonatal thrombocytopenia. Br J Haematol 2009;144:619-21.
39. McDonald TP, Cottrell MB, Steward SA, et al. Comparison of platelet production in two strains of mice with different modal megakaryocyte DNA ploidies after exposure to hypoxia. Exp Hematol 1992;20: 51-6.
40. Meberg A. Transitory thrombocytopenia in newborn mice after intrauterine hypoxia. Pediatr Res 1980;14: 1071-3.
41. Ohls RK, Ehrenkranz RA, Wright LL, et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics 2001;108:934-42.
42. Guida JD, Kunig AM, Leef KH, et al. Platelet count and sepsis in very low birth weight neonates: is there an organism-specific response? Pediatrics 2003;111:1411-15.
43. Manzoni P, Mostert M, Galletto P, et al. Is thrombocytopenia suggestive of organism-specific response in neonatal sepsis? Pediatr Int 2009;51:206-10.
44. Murray NA, Howarth LJ, McCloy MP, et al. Platelet transfusion in the management of severe thrombocytopenia in neonatal intensive care unit patients. Transfus Med 2002;12:35-41.
45. Modanlou HD, Ortiz OB. Trombocytopenia in neonatal infection. Clin Pediatr (Phila) 1981;20:402-7.
46. Dohner ML, Wiedmeier SE, Stoddard RA, et al. Very high users of platelet transfusions in the neonatal intensive care unit. Transfusion 2009;49:869-72.
47. Harker LA, Slichter SJ. Platelet and fibrinogen consumption in man. N Engl J Med 1972;287:999-1005.
48. Tate DY, Carlton GT, Johnson D, et al. Immune thrombocytopenia in severe neonatal infections. J Pediatr 1981;98:449-53.
49. Brown RE, Rimsza LM, Pastos K, et al. Effects of sepsis on neonatal thrombopoiesis. Pediatr Res 2008;64: 399-404.
50. Steinberg HN, Anderson J, Jr., Lim B, et al. Cytomegalovirus infection of the BS-1 human stroma cell line: effect on murine hemopoiesis. Virology 1993;196:427-32.
51. Crapnell K, Zanjani E D, Chaudhuri A, et al. In vitro infection of megakaryocytes and their precursors by human cytomegalovirus. Blood 2000;95: 487-93.
52. Isomura H, Yoshida M, Namba H, et al. Interaction of human herpesvirus 6 with human CD34 positive cells. J Med Virol 2003;70:444-50.
53. Srivastava A, Bruno E, Briddell R, et al. Parvovirus B19-induced perturbation of human megakaryocytopoiesis in vitro. Blood 1990;76:1997-2004.
54. Forestier F, Tissot J D, Vial Y, et al. Haematological parameters of parvovirus B19 infection in 13 fetuses with hydrops foetalis. Br J Haematol 1999;104:925-7.
55. Abzug M J. Prognosis for neonates with enterovirus hepatitis and coagulopathy. Pediatr Infect Dis J 2001;20: 758-63.
56. Hutter JJ, Jr., Hathaway WE, Wayne ER. Hematologic abnormalities in severe neonatal necrotizing enterocolitis. J Pediatr 1976;88:1026-31.
57. Ververidis M, Kiely EM, Spitz L, et al. The clinical significance of thrombocytopenia in neonates with necrotizing enterocolitis. J Pediatr Surg 2001;36: 799-803.
58. Frost BL, Jilling T, Caplan MS. He importance of pro-inflammatory signaling in neonatal necrotizing enterocolitis. Semin Perinatol 2008;32:100-6.
59. Caplan MS, Hedlund E, Adler L, et al. The platelet-activating factor receptor antagonist WEB 2170 prevents neonatal necrotizing enterocolitis in rats. J Pediatr Gastroenterol Nutr 1997;24:296-301.
60. Ropert JC, Dreyfus M, Dehan M, et al. [Severe neonatal thrombocytopenia. Analysis of the etiologic data on 64 cases]. Arch FrPediatr 1984;41:85-90.
61. Castle V, Coates G, Mitchell LG, et al. The effect of hypoxia on platelet survival and site of sequestration in the newborn rabbit. hromb Haemost 1988;59:45-8.
62. Hoffmeister KM, Felbinger TW, Falet H, et al. The clearance mechanism of chilled blood platelets. Cell 2003;112: 87-97.
63. Marks SD, Massicotte MP, Steele BT, et al. Neonatal renal venous thrombosis: clinical outcomes and prevalence of prothrombotic disorders. J Pediatr 2005;146:811-16.
64. Zigman A, Yazbeck S, Emil S, et al. Renal vein thrombosis: a 10-year review. J Pediatr Surg 2000;35:1540-2.
65. Enjolras O, Wassef M, Mazoyer E, et al. Infants with Kasabach-Merritt syndrome do not have “true” hemangiomas. J Pediatr 1997;130:631-40.
66. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007;357:580-7.
67. Spadone D, Clark F, James E, et al. Heparin-induced thrombocytopenia in the newborn. J Vasc Surg 1992;15:306-11; discussion 11-12.
68. Klenner AF, Fusch C, Rakow A, et al. Benefit and risk of heparin for maintaining peripheral venous catheters in neonates: a placebo-controlled trial. J Pediatr 2003;143:741-5.
69. Risch L, Huber AR, Schmugge M. Diagnosis and treatment of heparin-induced thrombocytopenia in neonates and children. hromb Res 2006;118:123-35.
70. Nguyen TN, Gal P, Ransom JL, et al. Lepirudin use in a neonate with heparin-induced thrombocytopenia. Ann Pharmacother 2003;37: 229-33.
71. Del Vecchio A, Sola MC, Teriaque DW, et al. Platelet transfusions in the neonatal intensive care unit: factors predicting which patients will require multiple transfusions. Transfusion 2001;41:803-8.
72. Garcia MG, Duenas E, Sola MC, et al. Epidemiologic and outcome studies of patients who received platelet transfusions in the neonatal intensive care unit. J Perinatol 2001;21:415-20.
73. Israels SJ, Odaibo FS, Robertson C, et al. Deficient thromboxane synthesis and response in platelets from premature infants. Pediatr Res 1997;41:218-23.
74. Rajasekhar D, Kestin AS, Bednarek FJ, et al. Neonatal platelets are less reactive than adult platelets to physiological agonists in whole blood. hromb Haemost 1994;72:957-63.
75. Andrew M, Castle V, Mitchell L, et al. Modified bleeding time in the infant. Am J Hematol 1989;30:190-1.
76. Boudewijns M, Raes M, Peeters V, et al. Evaluation of platelet function on cord blood in 80 healthy term neonates using the Platelet Function Analyser (PFA-100); shorter in vitro bleeding times in neonates than adults. Eur J Pediatr 2003;162:212-13.
77. Israels SJ, Cheang T, McMillan-Ward EM, et al. Evaluation of primary hemostasis in neonates with a new in vitro platelet function analyzer. J Pediatr 2001;138:116-19.
78. Roschitz B, Sudi K, Kostenberger M, et al. Shorter PFA-100 closure times in neonates than in adults: role of red cells, white cells, platelets and von Willebrand factor. Acta Paediatr 2001;90:664-70.
79. Del Vecchio A, Latini G, Henry E, et al. Template bleeding times of240 neonates born at 24 to 41 weeks gestation. J Perinatol 2008;28:427-31.
80. Bednarek FJ, Bean S, Barnard MR, et al. The platelet hyporeactivity of extremely low birth weight neonates is age-dependent. hromb Res 2009;124:42-5.
81. Josephson CD, Su LL, Christensen RD, et al. Platelet transfusion practices among neonatologists in the United States and Canada: results of a survey. Pediatrics 2009;123:278-85.
82. Kahn DJ, Richardson DK, Billett HH. Inter-NICU variation in rates and management of thrombocytopenia among very low birth-weight infants. J Perinatol 2003;23:312-16.
83. Andrew M, Vegh P, Caco C, et al. A randomized, controlled trial of platelet transfusions in thrombocytopenic premature infants. J Pediatr 1993;123:285-91.
84. Stanworth SJ, Clarke P, Watts T, et al. Prospective, observational study of outcomes in neonates with severe thrombocytopenia. Pediatrics 2009;124:e826-34.
85. Goldman M, Webert KE, Arnold DM, et al. Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev 2005;19:2-31.
86. Fatal bacterial infections associated with platelet transfusions - United States, 2004. Mmwr 2005;54: 168-70.
87. Baer VL, Lambert DK, Henry E, et al. Do platelet transfusions in the NICU adversely affect survival? Analysis of 1600 thrombocytopenic neonates in a multihospital healthcare system. J Perinatol 2007;27:790-6.
88. Bonifacio L, Petrova A, Nanjundaswamy S, et al. Thrombocytopenia related neonatal outcome in preterms. Indian J Pediatr 2007;74:269-74.
89. Kenton AB, Hegemier S, Smith EO, et al. Platelet transfusions in infants with necrotizing enterocolitis do not lower mortality but may increase morbidity. J Perinatol 2005;25:173-7.
90. Bussel JB, Mukherjee R, Stone AJ. A pilot study of rhuIL-11 treatment of refractory ITP. Am J Hematol 2001;66:172-7.
91. Kuter DJ. Hrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Ann Rev Med 2009;60:193-206.
92. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-47.
93. Bussel JB, Kuter DJ, George JN, et al. Amg 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672-81.
94. Pastos KM, Slayton WB, Rimsza LM, et al. Differential effects of recombinant thrombopoietin and bone marrow stromal-conditioned media on neonatal versus adult megakaryocytes. Blood 2006;108:3360-2.
95. Sola MC, Christensen RD, Hutson AD, et al. Pharmacokinetics, pharmacodynamics, and safety of administering pegylated recombinant megakaryocyte growth and development factor to newborn rhesus monkeys. Pediatr Res 2000;47:208-14.
96. Sola MC, Du Y, Hutson AD, et al. Dose-response relationship of megakaryocyte progenitors from the bone marrow of thrombocytopenic and non-thrombocytopenic neonates to recombinant thrombopoietin. BrJ Haematol 2000;110:449-53.